AR084263A1 - Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen) - Google Patents
Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen)Info
- Publication number
- AR084263A1 AR084263A1 ARP110104656A ARP110104656A AR084263A1 AR 084263 A1 AR084263 A1 AR 084263A1 AR P110104656 A ARP110104656 A AR P110104656A AR P110104656 A ARP110104656 A AR P110104656A AR 084263 A1 AR084263 A1 AR 084263A1
- Authority
- AR
- Argentina
- Prior art keywords
- dendritic cell
- bdca
- directed against
- antibody directed
- membrane protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Reivindicación 1: Anticuerpo monoclonal o policlonal dirigido contra la proteína BDCA-2 para su utilización en el área de la prevención o del tratamiento de patologías que implican una activación de las células dendríticas plasmocitoides, en donde dichas patologías son tumores hematopoyéticos de fenotipo CD4+, CD56+.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1060428A FR2968561B1 (fr) | 2010-12-13 | 2010-12-13 | Utilisation d'un anticorps dirige contre une proteine membranaire |
Publications (1)
Publication Number | Publication Date |
---|---|
AR084263A1 true AR084263A1 (es) | 2013-05-02 |
Family
ID=44140885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110104656A AR084263A1 (es) | 2010-12-13 | 2011-12-13 | Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen) |
Country Status (7)
Country | Link |
---|---|
US (1) | US20130315820A1 (es) |
EP (3) | EP3190127B1 (es) |
AR (1) | AR084263A1 (es) |
DK (1) | DK2651978T3 (es) |
ES (3) | ES2842526T3 (es) |
FR (1) | FR2968561B1 (es) |
WO (1) | WO2012080642A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2968561B1 (fr) | 2010-12-13 | 2013-08-09 | Lfb Biotechnologies | Utilisation d'un anticorps dirige contre une proteine membranaire |
RS60084B1 (sr) * | 2012-12-10 | 2020-05-29 | Biogen Ma Inc | Antitela anti-antigen 2 dendritske ćelije krvi i njihove upotrebe |
EP3083946A4 (en) * | 2013-12-16 | 2017-08-16 | The University of North Carolina at Chapel Hill | Depletion of plasmacytoid dendritic cells |
CN105829534B (zh) | 2013-12-24 | 2021-08-03 | 安斯泰来制药株式会社 | 抗人bdca-2抗体 |
FR3034420A1 (fr) * | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-cd303 |
US10215758B2 (en) | 2015-08-25 | 2019-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Platinum-labeled probes for mass cytometry |
FR3045386B1 (fr) * | 2015-12-16 | 2018-02-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation d'un anticorps dirige contre une proteine membranaire |
WO2024010118A1 (ko) * | 2022-07-07 | 2024-01-11 | 주식회사 유틸렉스 | 항 bdca-2 항체 및 이의 용도 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1060428A (fr) | 1952-07-19 | 1954-04-01 | Perfectionnements aux nez de lances d'incendie et analogues | |
CN1454215B (zh) | 1999-11-15 | 2013-01-02 | 米勒腾尼生物技术有限公司 | 树突状细胞特异的抗原结合片段、组合物及其使用方法、被其识别的抗原及由其获得的细胞 |
CA2392400A1 (en) * | 1999-11-24 | 2001-05-31 | Immunex Corporation | A human normal counterpart of cd4+ cd56+ cutaneous neoplasm |
EP2092939A3 (fr) † | 2002-09-13 | 2011-12-21 | LFB Biotechnologies | Utilisation thérapeutique d'anticorps induisant la production de cytokines |
US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
BRPI0516470A (pt) * | 2004-10-07 | 2008-09-09 | Universitot Zuerich | uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase |
US20080311034A1 (en) † | 2007-04-30 | 2008-12-18 | Anderson Glenn M | Anti-Tissue Factor Antibodies and Compositions with Enhanced Effector Function |
FR2968561B1 (fr) | 2010-12-13 | 2013-08-09 | Lfb Biotechnologies | Utilisation d'un anticorps dirige contre une proteine membranaire |
RS60084B1 (sr) † | 2012-12-10 | 2020-05-29 | Biogen Ma Inc | Antitela anti-antigen 2 dendritske ćelije krvi i njihove upotrebe |
FR3034420A1 (fr) † | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-cd303 |
-
2010
- 2010-12-13 FR FR1060428A patent/FR2968561B1/fr not_active Expired - Fee Related
-
2011
- 2011-12-12 ES ES17159253T patent/ES2842526T3/es active Active
- 2011-12-12 WO PCT/FR2011/052949 patent/WO2012080642A1/fr active Application Filing
- 2011-12-12 ES ES18192072T patent/ES2823201T3/es active Active
- 2011-12-12 EP EP17159253.8A patent/EP3190127B1/fr active Active
- 2011-12-12 DK DK11811089.9T patent/DK2651978T3/en active
- 2011-12-12 EP EP11811089.9A patent/EP2651978B2/fr not_active Not-in-force
- 2011-12-12 US US13/989,572 patent/US20130315820A1/en not_active Abandoned
- 2011-12-12 EP EP18192072.9A patent/EP3438129B1/fr active Active
- 2011-12-12 ES ES11811089.9T patent/ES2636969T3/es active Active
- 2011-12-13 AR ARP110104656A patent/AR084263A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2651978B1 (fr) | 2017-05-10 |
FR2968561B1 (fr) | 2013-08-09 |
ES2823201T3 (es) | 2021-05-06 |
EP2651978B2 (fr) | 2022-01-12 |
ES2842526T3 (es) | 2021-07-14 |
WO2012080642A1 (fr) | 2012-06-21 |
US20130315820A1 (en) | 2013-11-28 |
DK2651978T3 (en) | 2017-09-04 |
EP3190127A1 (fr) | 2017-07-12 |
ES2636969T3 (es) | 2017-10-10 |
EP3438129A1 (fr) | 2019-02-06 |
EP3438129B1 (fr) | 2020-07-22 |
EP3190127B1 (fr) | 2020-10-07 |
FR2968561A1 (fr) | 2012-06-15 |
EP2651978A1 (fr) | 2013-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR084263A1 (es) | Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen) | |
CY1123079T1 (el) | Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων | |
NZ765695A (en) | Immune cell organoid co-cultures | |
CY1122816T1 (el) | Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1 | |
CY1122676T1 (el) | Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου | |
CL2017000278A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
CY1120976T1 (el) | Δις ειδικα αντισωματα igg σαν παραγοντες ενεργοποιησης τ κυτταρων | |
PH12018500815A1 (en) | Antibody conjugates comprising toll-like receptor agonist | |
EA202091333A1 (ru) | Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний | |
CY1123051T1 (el) | Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους | |
BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
CU20120095A7 (es) | Antagonistas de pcsk9 | |
CU20170023A7 (es) | Anticuerpos y receptores de antígeno quiméricos específicos para cd19 | |
EA201590174A1 (ru) | Иммуноконъюгаты, содержащие анти-cd22 антитела | |
EA201390933A1 (ru) | Антитела против мезотелина и иммуноконъюгаты | |
CL2007003622A1 (es) | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. | |
EA201301180A1 (ru) | Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой | |
CY1117214T1 (el) | Συνθεση για ελεγχομενη διεγερση των ωοθηκων | |
ECSP13012673A (es) | Métodos y composiciones para inmunoterapia para enfermedad neural | |
BR112014002140A2 (pt) | anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer | |
FR2959994B1 (fr) | Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii | |
EA201400447A1 (ru) | АНТИТЕЛА К CD1d | |
CL2008003525A1 (es) | Conjugado de anticuerpo monoclonal humano anti-rg1 o una porcion de union a antigeno del mismo con moleculas asociadas, composicion que lo comprende; metodo in vitro para inhibir el crecimiento de una celula tumoral que expresa rg-1; uso de dicho conjugado para tratar el cancer | |
CY1126032T1 (el) | Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |